MiR-10b Downregulates the Stress-Induced Cell Surface Molecule MICB, a Critical Ligand for Cancer Cell Recognition by Natural Killer Cells

Pinchas Tsukerman, Noam Stern-Ginossar, Chamutal Gur, Ariella Glasner, Daphna Nachmani, Yoav Bauman, Rachel Yamin, Alon Vitenshtein, Noah Stanetsky, Tomer Bar-Mag, Dikla Lankry, and Ofer Mandelboim

Abstract

Natural killer cells (NK) are a component of innate immunity well known for their potent ability to kill virus-infected or neoplastically transformed cells following stimulation of the NK cell receptor NKG2D. One of the various ligands of NKG2D is MICB, a stress-induced ligand that has been found to be upregulated on the surface of tumor cells. However, there is little knowledge about how this upregulation may occur or how it may be selected against in tumors as a mechanism of immune escape. Here, we report that the metastasis-associated microRNA (metastamir) miR-10b directly binds to the 3' untranslated region of MICB and downregulates its expression. Notably, antagonizing miR-10b action enhanced NKG2D-mediated killing of tumor cells in vitro and enhanced clearance of tumors in vivo. Conversely, overexpression of miR-10b downregulated MICB and impaired elimination of tumor cells. Together, our results define MICB as a novel immune target of miR-10b, implying a direct link between metastasis capability and immune escape from NK cells. Cancer Res; 72(21); 5463–72. ©2012 AACR.

Introduction

MiRNAs are short noncoding RNA molecules that usually repress gene expression, by binding to their target mRNAs [mainly in the 3' untranslated region (UTR)] and either repress translation, or cause mRNA degradation (1, 2). The miRNAs' effect is moderate; nevertheless, these molecules are important gene regulators (3–5) and it is estimated that the activity of more than 50% of all cellular genes is controlled by miRNAs (5). MiRNAs can be either beneficial or detrimental to the developing tumors as they could serve either as tumor suppressors or as tumor initiators (6–10). MiRNAs are also involved in the metastatic process and the capacity of several miRNAs to initiate and to promote metastasis formation set the term "metastamir" (11–13). The most prominent metastamirs are: miR-10b, miR-21, miR-210, miR-373, and miR-520d (11–14). Among these miRNAs, miR-10b is probably the most famous one as it promotes both invasion and metastasis in various types of cancers by targeting multiple genes (15–18). Surprisingly, miR-10b is also expressed in the majority of normal tissues (19). Furthermore, it is significantly downregulated in the initial process of breast cancer initiation and is later upregulated in tumor metastases (20, 11). These observations suggest that miR-10b also functions under normal conditions; however, its role under these conditions is poorly understood.

Developing tumors are sensed by both innate and adaptive immune cells (21). Natural killer (NK) cells, which are part of the innate immune system, are known for their capacity to kill various tumor cells (22, 23). NK cell activity is controlled by a balance of signals derived from inhibitory and activating receptors (24, 25). One of the most powerful activating receptors expressed by NK cells (and also by subsets of T cells) is NKG2D (26, 27). This receptor recognizes stress-induced ligands that appear on the cell surface following various stresses, such as viral infection and cell transformation (28). The human stress-induced ligands include the major histocompatibility complex class I polypeptide–related sequences A and B (MICA and MICB, respectively) and the UL16-binding proteins (ULBP) 1–6 (28–30). Numerous mechanisms were developed by tumors and by viruses to escape NKG2D-mediated recognition, emphasizing the importance of this receptor (29, 31–35). For example, several distinct cellular and viral miRNAs were shown to target MICB, MICA, and ULBP3 to evade the NKG2D-mediated elimination (31–35).

The identification of miRNA targets is a difficult task. This difficulty arises because miRNAs are not fully matched with their target mRNAs and because the exact mechanisms controlling miRNA-mRNA interactions are not fully understood. Most algorithms that were so far developed to predict miRNA targets are very inaccurate with a false positive rate of about 65% (36).

Because several of the cellular MICB/A-targeting miRNAs are overexpressed in tumors (35) and as NKG2D plays an important role in tumor cell recognition, we wondered whether tumors might use metastamirs not only to promote the
generation of the metastatic phenotype but also to facilitate evasion from immune detection, by targeting the stress-induced ligands of NKG2D. Here, we show that MICB is targeted by the metastamir miR-10b and that such targeting leads to tumor escape from NK cell attack.

Materials and Methods

Lentiviral constructs, production, and transduction

Artificial RNA hairpins that function as pre-miRNA hairpins were generated by using the pTER vector as previously described (37). Sponge constructs were generated by annealing the oligonucleotides, phosphorylating them using T4 polynucleotide kinase, and inserting them into the pcDNA3 vector (Invitrogen). The sponges were excised and cloned into the lentiviral vector SIN18-pRLL-hEFlap EGFP-WRPE (38), down-stream to the GFP cassette. Each sponge consists of 6 adjacent binding sites for the relevant viral miRNA, separated by a 4 nucleotide (AGAG) spacer (Hannon 2008). The sequences of the sponges binding site: sponge anti–hsa-miR-10b: (5'-3') CACAAATCGGAAGACAGGGTA; Sponge anti–miR-BART 1-5p (control): CACACGACGTGAGAACACTAAGA. The MICB coding sequence was inserted into the SIN18-pRLL-hEFlap EGFP-WRPE instead of the GFP as previously described (35). Lentiviral vectors were produced as previously described (35).

Cytotoxicity assays and NK cell preparation

The cytotoxic activity of NK cells against various targets was assessed for 5 hours in 35S methionine release assays as previously described (35). The final concentration of the blocking antibodies was 2.5 mg/mL. NK cells were isolated from peripheral blood using the human NK cell isolation kit and the autoMACS instrument (Miltenyi Biotec) according to the manufacturer’s instructions.

Cell lines and antibodies

The following cell lines were used: HeLa (ATCC number CCL-2), PC-3 (ATCC number CRL-1435), DU 145 (ATCC number HTB-81), HEK 293T (ATCC number CRL112-68), RKO (ATCC number CRL-2577), MDA-MB-231 (ATCC number HTB-26), and MCF7 (ATCC number HTB-22). All cell lines in this work were obtained from and validated by the American Type Culture Collection and maintained as per instructions. The anti-MICA, anti-MICB (MAB1599; no cross-reaction with any of the stress ligands), anti–ULBP1-3, and anti-NKG2D antibodies were all purchased from R&D Systems. The anti–CD99 (12E7) was used as an isotype control. The anti-NKG2D hybridoma C7 used for the in vivo NKG2D blocking was kindly provided by Prof. M.W. Yokoyama (Washington University, St. Louis, MO) and S. Jonjic (University of Rijeka, Rijeka, Croatia). The anti-NK1.1 (PK136) was used for NK cells depletion.

Real-time PCR

Total RNA was isolated from various cell lines by using the Tri-Reagent (Sigma) and treated with RNase-free DNase-Turbo (Ambion). The RNA extraction and cDNA preparation were done as previously described (34). MiR-16 and U6 snRNA were used as the endogenous reference genes for PCR quantification. The reverse primer was a 3’ adapter primer (3’ RACE outer primer in the First Choice RLM-RACE Kit), and the forward primer was designed based on the entire miRNA sequence. For hsa-miR-10b: 5'- TACCCGTGAGAACCAGATTTGTG 3’. The relative expression was calculated by qbase algorithm when lowest expression was set to 1 in the miRNAs. The MICB mRNA levels were quantified using MiRCP specific Taqman Gene Expression Kit by Ambion according to the manufacturer’s instructions. hypoxanthine phosphoribosyltransferase was used as a control gene.

DNA constructs and luciferase assay

For the firefly luciferase vector, we used the pGL3 control vector (Promega). The 3’UTR of MICB was generated as described (35) Xba I site immediately downstream to a stop codon. The inserts and their proper orientation were confirmed by sequencing. The mutation in has-miR-10b was generated using following primers: FW 5’ TTCATGTCATAGG CACCCTGTAGAACGGAAATTTGTG 3’ (control): CACACGACGTGAGAACACTAAGA. The luciferase assay was conducted as described (32).

Lung clearance assay

Male C57B/6 mice (9–10 weeks old) were divided into 3 groups and were injected IP with anti-mouse NKG2D mAb (C7) at a concentration of 300 μg per mouse, or with NKJ.1 (PK136), 150 μg per mouse or PBS. Twenty-four hours later, HeLa cells [cells that are not efficiently killed by mouse NK cells (40), thus serving as internal control] were labeled with the fluorescent dye Vybrant DiD (Molecular Probes) and the various PC-3 cells were labeled with the fluorescent dye CFSE (Molecular Probes). Cells were mixed at a density of 5 × 10⁶ cells of each population in 1 mL of PBS, and 400 μL was injected into the tail vein. Lungs were collected 5 hours later, single-cell suspensions were obtained with cell strainers, and fluorescence was analyzed by fluorescence-activated cell sorting (FACS). The ratio of tested target cells to HeLa cells was calculated. The ratio of the control vector injected cells to HeLa was set as 100%.

Results

MiR-10b specifically downregulates MICB expression

To investigate whether metastamirs are involved in immune regulation by targeting the stress-induced ligands of NKG2D, we used the TargetScan algorithm (41) and searched the 3’UTRs of the stress-induced ligands of NKG2D for potential binding sites of prominent metastasis-promoting miRNAs, miR-10b, miR-21, and miR-210. Potential binding sites were predicted in the 3’UTRs of MICB, ULBP1, and ULBP2 (Supplementary Fig. 1) with regard only to miR-10b, thus we continued our analysis with this miRNA.

MiR-10b and a control miRNA were cloned into lentiviral vectors that also contain a GFP cassette and the 2 miRNAs were transduced into RKO cells (the transduction efficiencies of all cell lines used in this article are shown in Supplementary Fig. 2). As can be seen in Fig. 1A and quantified in Fig. 1B, expression of miR-10b, resulted in about 50% downregulation of MICB expression compared with cells transduced with a control miRNA. It has previously been shown that the expression of miR-10b differs substantially between the 2 breast cancer lines,
MDA-MB-231 and MCF7 (11). After confirming these observations (Fig. 1C), the expression of miR-10b in MCF7 cells was set up as one. We have tested the surface expression levels of MICB in these 2 cell lines and observed that, in agreement with the above results, MICB levels were inversely correlated with the expression of miR-10b (Fig. 1D). We next overexpressed miR-10b in MCF7 cells (Supplementary Figs. 2 and 1E) and observed that this overexpression significantly reduced MICB expression (Fig. 1F). Although the TargetScan algorithm predicted that ULBP1 and ULPB2 can potentially be targeted by miR-10b (Supplementary Fig. 1), little, or no changes in the levels of these ligands or other NKG2D ligands was detected in the presence of miR-10b (Fig. 1G, figure shows only the stress-induced ligands that are expressed by this cell line). Therefore, we concluded that miR-10b specifically controls MICB expression.
MiR-10b directly binds to the 3' UTR of MICB

To test whether miR-10b targets MICB directly we generated 2 firefly luciferase constructs: one containing the wild-type 3' UTR of MICB and another one containing the 3' UTR of MICB, in which the miR-10b site [predicted by the TargetScan algorithm (Fig. 2A)] was mutated. These constructs were transiently transfected into RKO cells that were also transduced with miR-10b, or with a control miRNA. As can be seen in Fig. 2B, a moderate, yet significant decrease in luciferase activity was observed in the presence of miR-10b, whereas the mutations in the 3’ UTR of MICB abolished this effect, indicating that miR-10b indeed directly targets MICB at the predicted binding site.

To elucidate the mechanism accounting for the miR-10b-mediated downregulation of MICB we used quantitative real-time PCR (qRT-PCR) to evaluate the mRNA levels of MICB in RKO cells stably expressing miR-10b or a control miRNA. In agreement with our previous reports about the miRNA mode of regulation of the stress-induced ligands (34, 35), we observed no significant differences (Fig. 2C), suggesting that the miR-10b-mediated MICB downregulation probably occurs by translational repression.

Subtle changes in MICB expression affects NKG2D-mediated killing

The miRNA activity effect is generally moderate (3) and indeed the miR-10b-mediated downregulation of MICB was moderate as well, ranging between 20% and 50% depending on the cell line examined (see Fig. 1 and figures below). We were, therefore, interested to test whether moderate differences in MICB expression will affect the NKG2D-mediated killing by NK cells. For this purpose, we transduced 293T cells (that do not express MICB on their cell surface) with lentivirus expressing MICB and obtained 3 clones expressing various levels of MICB on their surface (Fig. 3A). The various MICB-expressing clones were then used in NK cytotoxicity assays. As can be seen in Fig. 3B and C subtle changes of around 20% of MICB expression were sufficient to cause a significant reduction in the NK-mediated killing of 293T cells (the raw killing data are presented in Supplementary Fig. 3). The MICB-dependent reduction of killing was due to reduced NKG2D recognition, because the killing of all clones was reduced to the levels of the parental 293T upon NKG2D blocking (Supplementary Fig. 3).

The downregulation of MICB by miR-10b results in reduced NKG2D-mediated killing

We next aimed to show that the miR-10b-mediated downregulation of MICB is functional and specific. We, therefore, initially tested whether the expression of miR-10b in a cell line deficient for MICB expression such as 293T (Supplementary Fig. 4) will alter either the expression of the NKG2D ligands or will affect the killing of these cells. As can be seen, overexpression of miR-10b did not induce the expression of MICB and it did not influence the expression of other NKG2D ligands such as MICA, ULBP2, and ULBP3 (Supplementary Fig. 4A). Furthermore, no difference in the killing of 293T cells was observed between miR-10b–transduced and control miR–transduced cells (Supplementary Fig. 4B).

Next, we tested the functional outcome of the miR-10b targeting of MICB by using various cell lines of diverse origins that are positive for MICB expression such as DU 145 cells (Fig. 4A), MCF7 (Fig. 4B), and RKO (Fig. 4C). The cells were transduced with miR-10b or with a control miR (the transduction efficiency is shown in Supplementary Fig. 2) and as can be seen in Fig. 4A–C, column 1, quantified in Fig. 4A–C, column 2, a reduction in MICB expression was noticed in all cell lines following the miR-10b overexpression. Furthermore, the miR-10b–mediated reduction was specific as the expression of other NKG2D ligands was not altered following the miR-10b transduction (Fig. 1G and Supplementary Fig. 5, figure shows only the NKG2D ligands that are expressed by these cells).

Next, we tested whether the miR-10b–mediated reduction of MICB expression is functional. For that we used all cell lines transduced with miR-10b in NK cytotoxicity assays. As can be
Reduced GFP intensity. Indeed, as can be seen in Fig. 5A and thus the sequestration of the relevant miRNA leads to sponge is located downstream to the GFP open reading frame the miRNA effect through target site competition (42). targeting by the relevant miRNA, but it rather titrates some of because the sponge does not completely prevent the MICB expressed by these cells. The sponge effect is moderate expressed by these cells expressing the highest median miR-10b were transduced with either the miRNA sponge technique that enables us to antagonize the activity of a certain miRNA (42). HeLa cells and PC-3 cells that targeting of MICB was speciﬁed mice, as miR-10b is very well known for its tumoro-
cient mice (Fig. 5A). Twenty-four hours later, the various mice were injected with either PC-3 cells expressing the highest median expression and consequently to reduced killing by NK cells.

**MiR-10b endogenously controls MICB expression**

We next wanted to show that MICB expression is endogenously controlled by miR-10b. For this purpose, we used the miRNA sponge technique that enables us to antagonize the activity of a certain miRNA (42). HeLa cells and PC-3 cells that express moderate levels of miR-10b and DU 145 cells that express high levels of miR-10b were transduced with either the anti-miR-10b sponge, or with a control sponge (the transduction efficiency is shown in Supplementary Fig. 2). As can be seen in Fig. 5A–C, column 1, quantified in 5A–C, column 2 the expression of the miR-10b sponge leads to a moderate elevation of about 25% in MICB expression. The increased expression of MICB was speciﬁc and signiﬁcant as the expression of other NKG2D ligands did not change (Supplementary Fig. 6, the ﬁgure show only the staining of NKG2D ligands that are expressed by these cells). The sponge effect is moderate because the sponge does not completely prevent the MICB targeting by the relevant miRNA, but it rather titrates some of the miRNA effect through target site competition (42).

One of the major advantages of the sponge technique is that it also enabled us to monitor for the sponge activity. The sponge is located downstream to the GFP open reading frame and thus the sequestration of the relevant miRNA leads to reduced GFP intensity. Indeed, as can be seen in Fig. 5A–C, column 3, the anti–miR-10b sponge indeed sequestered miR-

10b as the GFP intensity of this sponge was signiﬁcantly reduced in all lines tested as compared with control sponge.

Finally, we showed that the miR-10b–mediated sponge elevation of MICB expression is functional, as killing of the miR-10b sponge–transduced cells was enhanced in all lines tested (Fig. 5A–C–4). The increased effect was NKG2D dependent as blocking of NKG2D abolished the observed differences (Fig. 5C–4).

**MiR-10b–mediated immune evasion in vivo**

Our next aim was to show the signiﬁcance of the miR-10b targeting of MICB in vivo. This is a diﬁcult task because the human NKG2D ligands are different from those of the mouse and MICB is not expressed by mouse cells (43, 44). Furthermore, the 3′ UTRs of the mouse and human NKG2D ligands are different and no sites are predicted for miR-10b in the 3′UTRs of the mouse NKG2D ligands. Indeed, overexpression of miR-10b in the mouse B12 cells did not decrease the levels of mouse stress-induced ligands (data not shown). In addition, it is very difﬁcult to examine the immune mediated effect of miR-10b in long-term assays using human xenograft implanted in T-cell–deﬁcient mice, as miR-10b is very well known for its tumorigenic and metastatic properties. Thus, it would be very difﬁcult to interpret the results that relate to the immune activity of miR-10b using long-term human xenograft assays.

On the other hand, testing the activity of NKG2D-related functions on human tumors is feasible in immunocompetent mice model as the murine NKG2D receptor recognizes the human ligands and vice versa (35). Thus, to evaluate the miR-10b–mediated immune effect in vivo we used a short term in vivo assay (illustrated in Fig. 6A). C57B/6 mice were injected either with PBS, with a blocking anti-NKG2D mAb [which does not lead to immune cell depletion (45)], or with anti-NK1.1 antibody for the depletion of NK cells, at time point zero (Fig. 6A). Twenty-four hours later, the various mice were intravenously (i.v.) injected with either PC-3 cells expressing...
miR-10b (the specific downregulation of MICB is shown in Fig. 6B and Supplementary Fig. 7), PC-3 cells expressing a control vector, or PC-3 expressing an anti–miR-10b sponge (the specific upregulation of MICB is shown in Fig. 6B and Supplementary Fig. 7). As i.v. injections might vary between the different mice, it is essential to use an internal control. Therefore, in each injection, we mixed the tested PC-3 cells, which were labeled with one fluorescent dye, together with HeLa cells that were hardly killed by mouse NK cells (40) and that were labeled with a different fluorescent dye, and injected them i.v. into the various mice groups (Fig. 6A). The labeled cells reached the lungs of the injected mice within less than 1 minute (ref. 40 and Supplementary Fig. 8A) and the in vivo killing of the various cells was conducted in the lungs. The lungs of the injected mice were harvested 5 hours later, enabling us to examine the function of mainly innate immune cells, such as NK cells. Cell suspensions from the lungs were obtained and analyzed by FACS.

Importantly, we observed that the miR-10b–mediated downregulation of MICB was significant in this in vivo setting because, as can be seen in Fig. 6C, left, significantly more PC-3 cells overexpressing miR-10b were present in the lungs of the injected mice as compared with PC-3 cells expressing a control miRNA (miR-10b downregulates MICB, therefore, less cells are killed and more cells are present in the lungs). A reciprocal picture was observed when the miR-10b activity was antagonized by the miR-10b sponge as this led to a significantly lower tumor cell survival in the lungs (the miR-10b sponge leads to increased MICB expression and, therefore, increased killing). The differences observed were due to NKG2D recognition as the in vivo blocking of NKG2D activity by anti-NKG2D mAb abolished the effects observed (Fig. 6C, middle). Furthermore,
NK cells are the main responders in this setting as the experiments were conducted for 5 hours only (enabling the activity of mainly innate immune cells) and because the depletion of NK cells by the anti-NK1.1 mAb completely abolished the effects observed (Fig. 6C, right). Examples of the raw data are presented in Supplementary Fig. 8. Thus, the miR-10b-mediated reduction of MICB protects tumor cells from immune recognition in vivo.

Discussion
Tumors have developed various mechanisms to escape immune cell–mediated elimination (21). Prominent among these is the reduction of MHC class I expression to avoid CTL attack (46). However, evading CTL attack in such a manner renders the tumor cells susceptible to NK cell–mediated eradication, because NK cell killing is inhibited by MHC class I–binding inhibitory receptors (25, 44). To overcome the NK cell attack, tumors also developed mechanisms to inhibit the NK cell activity, which includes, for example, the upregulation of HLA-G to inhibit NK cytotoxicity (46), and the downregulation of killer ligands for NKG2D and Nkp46 (35, 44, 47) to escape the killer receptor recognition.

In recent years, it was realized that several miRNAs contribute significantly to tumor spread and metastasis, hence these miRNAs were named oncomirs or metastamirs. Here, we identified a novel immune target for one of the most prominent metastamirs known to date, miR-10b. We show in vitro that miR-10b targets the 3’ UTR of MICB and not other stress-induced ligands and that this results in diminished NKG2D recognition and consequently reduced tumor cell killing by NK cells. We showed that the miR-10b–mediated downregulation of MICB resulted in reduced NK cell elimination in vivo through reduced recognition of NKG2D. This was a challenging task as MICB is not expressed in mice, the murine stress ligands are not targeted by miR-10b and it is quite difficult to assess the immune function of miR-10b as this miRNA is very well known for its prominent role in promoting tumor progression and metastases.
We have previously identified other cellular miRNAs that target MICB (32, 35). The various MICB-targeting miRNAs share several features: First, all cellular MICB-targeting miRNAs inhibit its expression probably through inhibition of translation. Second, cells expressing each of the MICB-targeting miRNAs are killed less efficiently. Still, among the various MICB-targeting miRNAs, miR-10b seems to be a unique miRNA. Its binding site is located in the middle of the 3’ UTR of MICB and not at the edges as all other MICB-targeting miRNAs (32, 35). Furthermore, for all other MICB-targeting cellular miRNAs, viral miRNAs were identified that bind MICB in sites overlapping with the cellular miRNA-binding sites (32, 35). In contrast, no viral miRNAs were identified that target MICB at sites overlapping with that of miR-10b. Recent work by the Weinberg group showed that antagonizing miR-10b activity in vivo restores the levels of the transcription factor HOXD10 and reduces metastases formation (48, 49). Here, we show that a competitive inhibitor (sponge) directed against miR-10b led to the upregulation of MICB on the surface of tumor cells, resulting in significant clearance of tumor cells in vivo. Thus, we suggest that antagonizing miR-10b activity during tumor development may lead to reduction of metastases formation through dual mechanism by enhancing the expression of the transcription factor HOXD10 and by boosting the NKG2D-mediated immune attack.

In conclusion, we show here that the metastamir miR-10b targets MICB to avoid the NKG2D-mediated immune attack. NKG2D is expressed not only by NK cells but also by CD8+ T cells where it functions as costimulatory molecule (50). Thus, targeting of MICB by miR-10b is a novel and general immune evasion mechanism that links directly metastases formation and immune evasion.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: P. Tsukerman, N. Stern-Ginossar, O. Mandelboim
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Glaser, Y. Bauman, N. Stanetsky, T. Bar-Mag, D. Lankry

Analysis and interpretation of data (e.g., statistical analysis, bioinformatics, computational analysis): P. Tsukerman, A. Vitenshtein, O. Mandelboim

Writing, review, and/or revision of the manuscript: P. Tsukerman, Y. Bauman, Y. Yamin, A. Vitenshtein, N. Stanetsky, O. Mandelboim

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Gur, D. Lankry

Study supervision: O. Mandelboim

Acknowledgments

The authors thank Mazal Elnekave for assistance in the in vivo experiments.

References

12. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an

Grant Support

This study was supported by grants from the Israel Science Foundation, The ICRF, by the Rosetrees trust, by the Association for International Cancer Research (AICR), and by the I-CORE Program of the Planning and Budgeting Committee, The Israel Science Foundation (grant number 41/11). O. Mandelboim is a Crown professor of Molecular Immunology.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 8, 2011; revised July 5, 2012; accepted August 6, 2012; published OnlineFirst August 21, 2012.

www.aacrjournals.org

Cancer Res; 72(21) November 1, 2012
5471

Published OnlineFirst August 21, 2012; DOI: 10.1158/0008-5472.CAN-11-2671

Downloaded from cancerres.aacrjournals.org on April 14, 2017. © 2012 American Association for Cancer Research.
Killer Cells

MICB, a Critical Ligand for Cancer Cell Recognition by Natural Killer Cells

Pinchas Tsukerman, Noam Stern-Ginossar, Chamutal Gur, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-2671

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/08/21/0008-5472.CAN-11-2671.DC1

Cited articles
This article cites 49 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/21/5463.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/72/21/5463.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.